SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is seeing extreme volatility and record volume as the community debates the impact of a lawsuit from Novo Nordisk over its compounded GLP-1 medication and Hims' subsequent withdrawal of the product. Bulls view the steep drop as an oversold buying opportunity, while bears anticipate further declines amid escalating legal and regulatory pressures, especially as Novo Nordisk itself faces an FDA warning regarding its Wegovy ad.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean is trending following its all-stock acquisition of Valaris, a $5.8 billion deal set to create a combined $17 billion offshore drilling industry leader. The community is actively discussing the potential for a strengthened fleet and significant cost savings to capitalize on an emerging upcycle, though some express concerns over shareholder dilution.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies ($PGY) is trending due to a significant market sell-off following its Q4 earnings, where conservative guidance for the coming year overshadowed stronger-than-expected profitability. The community is debating whether this reflects an extreme overreaction to management's focus on prudent risk management or a deeper concern within the AI-powered fintech sector.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com is trending after issuing weaker-than-expected revenue guidance for the current quarter and fiscal year, despite a strong earnings beat, intensifying investor concerns that AI is disrupting the traditional software business model. The community is sharply divided, with many viewing the steep selloff as an overreaction and a buying opportunity given the company's cash position, while others remain cautious about AI's long-term impact on the SaaS sector.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl (KD) is plummeting amid news of its CFO and General Counsel's departure, delayed financial filings, a reduced 2026 revenue outlook, and an SEC probe into accounting, sparking a community debate between dip-buyers who see an overreaction and others fearing deeper governance issues.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending due to a striking disconnect between recent strong earnings, profitability, and a $500M share buyback, and an unprecedented streak of red daily candles pushing the stock to historic lows. Community sentiment is fiercely divided on whether this presents a generational buying opportunity fueled by its AI/AR smartglasses vision and a potential short squeeze, or if persistent management issues will continue to suppress its value.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

ELF Beauty is trending amidst a surprising stock drop following strong earnings and raised guidance, prompting community debate on whether a recent advertisement or market overreaction is to blame for the 'senseless dip' that many investors are seizing as a buying opportunity.

Tokenized asset from Ondo Finance representing BigBear.ai Holdings (Ondo Tokenized).

BigBear.ai Holdings (Ondo Tokenized Stocks)

Community engagement is driving discussion around BBAION CRYPTO, with a noticeable increase in 'watchers' actively aiming to amplify its trend, linking it closely to the broader BigBear.ai ecosystem.

Jack in the Box, Inc. engages in the provision of developing, operating, and franchising a chain of quick-service and fast-casual restaurants. It operates through the Jack in the Box and Del Taco segments. The Jack in the Box segment offers a selection of distinctive products including classic burgers and other product lines such as Buttery Jack Burgers. The company was founded by Robert Oscar Peterson in 1951 and is headquartered in San Diego, CA.

Jack In The Box, Inc.

Jack In The Box is trending following recent weak earnings and the strategic, yet controversial, sale of Del Taco aimed at reducing its significant debt load. The company's adoption of a poison pill to deter an activist investor is fueling community speculation about a potential short squeeze and the success of its ongoing turnaround plan.

AECOM engages in the design, manufacture, financing, and operation of infrastructure assets for governments, businesses, and organizations. It operates through the following segments: Americas, International, and AECOM Capital. The Americas segment deals with planning, consulting, architectural and engineering design, construction management, and program management services to public and private clients in the United States, Canada, and Latin America in major end markets such as transportation, water, government, facilities, environmental, and energy. The International segment focuses on planning, consulting, architectural and engineering design services and program management to public and private clients in Europe, the Middle East, India, Africa, and the Asia-Australia-Pacific regions in major end markets such as transportation, water, government, facilities, environmental, and energy. The AECOM Capital segment is involved in investing and developing real estate projects. The company was founded on January 31, 1980 and is headquartered in Dallas, TX.

AECOM

AECOM is trending following strong earnings reports, record backlogs, and substantial global infrastructure contract wins, notably in environmental services and smart city development through its partnership with Gorilla Technology. The company's increased dividend and share buyback program, alongside its strategic focus on high-margin services, are fueling community discussion about its potential as an undervalued play in the ongoing infrastructure boom.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vincerx Pharma ($VINC) shares were in the spotlight over the weekend following the company’s proposed merger with Oqory, a privately-held, clinical-stage company that develops ADCs for the treatment of multiple oncology conditions, with retail sentiment staying strong.Vincerx stock was up 64% in after-hours trading session on Friday.Upon completion of the proposed merger, Oqory equity holders are expected to own approximately 95% of the combined entity, while Vincerx equity holders will hold about 5%.Vincerx plans to reduce its workforce and undertake cost-control measures, the company said. As part of this workforce reduction, its CEO Dr. Ahmed Hamdy has stepped down but will remain as chairman. Dr. Raquel Izumi has stepped down as president and COO and taken over as acting CEO in a consulting capacity; Alexander Seelenberger has stepped down as CFO.Retail sentiment on Stocktwits has remained ‘bullish’ on the stock. Message volumes are in the ‘normal’ zone.<figure class="image"><img style="aspect-ratio:1256/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_30_at_10_18_33_AM_bd88e280b0.png" alt="Screenshot 2024-12-30 at 10.18.33 AM.png" width="1256" height="302"><figcaption>VINC sentiment meter and message volumes on Dec 29 as of 11:45 pm ET</figcaption></figure><stembedurl>https://stocktwits.com/jlemx/message/598101092</stembedurl>The merger is subject to customary closing conditions and the completion of the minimum $20 million in financing, and the continued listing of Vincerx's common stock on Nasdaq.According to a Vincerx statement, the transaction includes a minimum fully diluted equity value of $13.66 million for existing Vincerx stockholders.Additionally, certain Oqory-designated investors will provide interim financing to Vincerx of $1.5 million in two tranches.The financing consists of about $1 million funded through the issuance of common stock and pre-funded warrants along with accompanying common stock warrants and approximately $500,000 funded on or prior to January 31, 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Vincerx Pharma Stock Rises On Proposed Merger With Oqory: Retail Remains Bullish

 Retail sentiment on Stocktwits has remained ‘bullish’ on the stock. 

Equity

Shares of Vincerx Pharma saw volatile trading on Wednesday, swinging between gains and losses after the company unveiled significant cost-cutting measures.&nbsp;The moves are aimed at advancing its VIP943 program, a cancer treatment for leukemias and myelodysplastic syndrome, the company said.Vincerx CEO Ahmed Hamdy reiterated the company’s commitment to VIP943, highlighting positive early results from the Phase 1 dose-escalation study.&nbsp;The trial showed promising safety and efficacy, with a relapsed AML patient achieving complete remission with incomplete blood count recovery (CRi) and a higher-risk MDS patient achieving complete remission with leukemic cells (CRL).&nbsp;Notably, the CRi patient showed significant improvement, with their bone marrow revealing only 1% cancer cells after seven months.To ensure the continued development of VIP943, Vincerx is taking aggressive steps to streamline operations and focus resources on the trial’s advancement.&nbsp;That includes a 55% reduction in force and exploring strategic alternatives such as out-licensing, mergers, or asset sales.&nbsp;The company also announced plans to engage a financial advisor to guide the strategic review process.<figure class="image"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/VINC_sentiment_and_message_volume_Dec_4_196f59dc07.png" alt="VINC sentiment and message volume Dec 4 .png" width="1318" height="318"><figcaption>VINC sentiment and message volume Dec 4 as of 10:45 am ET | source: Stocktwits</figcaption></figure>Retail activity surrounding VINC surged, with message volume on Stocktwits reaching the second-highest level in the past year, while sentiment remained ‘bullish’.&nbsp;One watcher speculated that a reverse stock split or partnership deal could be in the works.<stembedurl>https://stocktwits.com/HoHoHoHum/message/594996367</stembedurl><a href="https://stocktwits.com/symbol/VINC">Vincerx’s stock</a> has struggled, losing over 75% of its value year-to-date.&nbsp;As of Oct. 31, the company had $8.4 million in cash and is actively pursuing partnerships to advance other oncology treatments, including VIP236 for solid tumors and enitociclib for leukemia.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail activity surrounding VINC surged, with message volume on Stocktwits reaching the second-highest level in the past year.

Vincerx Pharma Stock Gets Retail Followers Buzzing With Big Layoff Plans To Sustain Cancer Drug Trials 

The company's plans include a 55% reduction in force and exploring strategic alternatives such as out-licensing, mergers, or asset sales.

Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. It focuses on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The firm pipeline is derived from a license agreement with Bayer and includes: a clinical-stage and follow-on small molecule drug program and preclinical stage bioconjugation/next-generation antibody-drug conjugate platform. The company was founded by Ahmed M. Hamdy, Raquel E. Izumi, Tom C. Thomas, Soo In Hwang and John C. Byrd on December 19, 2018 and is headquartered in Palo Alto, CA.

Vincerx Pharma Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

VINC
Vincerx Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VINC News

VINCVincerx Pharma Inc